Ertem et al 1 reported that serum procalcitonin (PCT; an indicator of systemic inflammation) is an independent predictor of a high SYNTAX (SX) score in patients with acute coronary syndrome (ACS; P < .001). Because patients with a higher SX score had higher serum PCT levels on admission, they proposed that serum PCT level might stratify patients with more complex coronary artery disease (CAD).
The SX score represents various anatomical and morphological characteristics of the coronary vasculature with respect to the number of lesions and their functional impact, location, and complexity. 2, 3 Initially, the score was developed to predict prognosis in patients undergoing elective percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Patients with higher SX scores, indicating more complex disease, have potentially worse prognosis. 4 However, the score has also been shown to predict short-and long-term cardiovascular prognosis in patients with ACS. 5, 6 It is also known that the frequency of multi-vessel complex CAD was much higher in patients with non-ST-segment elevation ACS compared to patients with ST-segment elevation ACS. 7 Therefore, Ertem et al 1 should analyze the results separately for both ST-segment elevation and non-ST-segment elevation ACS patient groups. Second, the authors should provide details about the presence of clinical presentation with cardiac arrest, acute decompensated heart failure, and cardiogenic shock. In previous studies, it has been shown that serum PCT levels were significantly higher among such patients. [8] [9] [10] Third, how did the authors ensure the exclusion of infection in the presence of high serum PCT levels? It is crucial for clinicians to decide when increased serum PCT levels are due to ACS or other reasons. Therefore, additional biomarkers, clinical data, or imaging tools may be needed when reaching a definitive diagnosis. Finally, serum PCT levels might be increased in cases of impaired renal function. 11 It was clear from the Ertem et al 1 study that patients with higher SX score had higher serum creatinine levels.
In conclusion, serum PCT, as an indicator of systemic inflammatory reaction, may be used as a gatekeeper for prediction of more complex CAD among patients with ACS. However, confounding factors should be considered when interpreting these levels.
